Vascular toxicity of phosphate in chronic kidney disease: beyond vascular calcification

Area of Science:

• Nephrology
• Cardiovascular Medicine
• Biochemistry

Background:

• Chronic kidney disease (CKD) is associated with increased cardiovascular morbidity and mortality.
• Vascular calcification (VC) and endothelial dysfunction (ED) are key contributors to cardiovascular complications in CKD.
• Hyperphosphatemia, a common feature of CKD, is implicated in the pathogenesis of VC and ED.

Purpose of the Study:

• To review the mechanisms by which hyperphosphatemia contributes to vascular calcification and endothelial dysfunction in CKD.
• To discuss the potential impact of lowering phosphate levels on cardiovascular outcomes in CKD patients.

Main Methods:

• Literature review of preclinical and clinical studies.
• Analysis of direct and indirect pathways of hyperphosphatemia-induced VC and ED.
• Consideration of roles for fibroblast growth factor 23 (FGF23) and parathyroid hormone (PTH).

Main Results:

• Hyperphosphatemia directly and indirectly promotes VC and ED in CKD.
• Phosphate influences VC and ED through various pathways, including FGF23 and PTH.
• The clinical benefit of phosphate-lowering strategies on VC and cardiovascular outcomes in CKD requires further investigation.

Conclusions:

• Hyperphosphatemia is a significant driver of vascular complications in CKD.
• Understanding the mechanisms of phosphate's role in VC and ED is crucial for therapeutic development.
• Targeting phosphate levels may offer a strategy to mitigate cardiovascular risk in CKD, but clinical validation is pending.